REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, December 7 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd , a leader in the development of microRNA-based diagnostics and therapeutics, announced today that Dr. Dalia Cohen, EVP, Global Head of R&D at Rosetta Genomics, will present at RBC Capital Markets 2007 Healthcare conference on Thursday, December 13, at 9:00 am EST at the Westin Hotel in New York.
A live audio webcast of the presentation will be available on the “Investors” section of the company’s website, http://www.RosettaGenomics.com. A replay of the presentation will be available for 30 days after the conference.
About Rosetta Genomics
Rosetta Genomics is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company’s primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and other indications. For more information please visit: http://www.rosettagenomics.com
media@rosettagenomics.cominvestors@rosettagenomics.com
CONTACT: Contact: Media: Alan Zachary, T: +1(312)-944-6784,
media@rosettagenomics.com. Investors: Juliane Snowden, T: +1(212)-213-0006,
investors@rosettagenomics.com
